Daiichi Sankyo
Daiichi Sankyo's Overview
Daiichi Sankyo Co., Ltd. is a global pharmaceutical company with a rich history of innovation, originating from Japan. The company focuses on the research, development, manufacturing, and marketing of pharmaceutical products worldwide. Their core mission is to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and provision of medicines addressing diverse medical needs. Key therapeutic areas include oncology (a primary focus), cardiovascular diseases, and specialty medicines. Daiichi Sankyo is committed to leveraging its cutting-edge science and technology to deliver new treatment options for patients, particularly in areas with high unmet medical needs.
Where is Daiichi Sankyo's Headquarters?
HQ Function
The global headquarters serves as the central command for Daiichi Sankyo's worldwide operations, overseeing corporate strategy, global R&D direction, finance, legal affairs, and overall group management.
Notable Features:
The Daiichi Sankyo Building is a modern, purpose-built facility reflecting the company's status as a leading pharmaceutical innovator. It likely incorporates advanced communication infrastructure and collaborative workspaces.
Work Culture:
The work culture at the Tokyo HQ likely blends traditional Japanese corporate values such as long-term vision, precision, and group harmony with the dynamic, science-driven, and increasingly globalized environment of the pharmaceutical industry. Emphasis is placed on quality, ethical conduct, and innovation.
HQ Significance:
Its location in Tokyo, a major global financial and business hub, and the heart of Japan's pharmaceutical industry, underscores Daiichi Sankyo's strong roots and its role as a key player in both the domestic and international healthcare landscape.
Values Reflected in HQ: The headquarters likely embodies Daiichi Sankyo's core values: 'Passion for Innovation, Compassion for Patients,' through its design fostering scientific advancement and efficient global coordination to serve patient needs.
Location:
Daiichi Sankyo has a robust global presence with research and development, manufacturing, and commercial operations spanning across Japan, North America (primarily the U.S.), Europe, Asia (including China, India, South Korea, Taiwan, Thailand, Vietnam, Brazil, and others), and other regions. Globally supported functions include drug discovery, clinical development, regulatory affairs, manufacturing and supply chain management, sales and marketing, and corporate support services. This widespread network enables the company to conduct global clinical trials, access diverse talent pools, and deliver its innovative medicines to patients worldwide.
Street Address:
Daiichi Sankyo Building, 3-5-1, Nihonbashi Honcho
City:
Chuo-ku, Tokyo
State/Province:
Tokyo
Country:
Japan
Daiichi Sankyo's Global Presence
Basking Ridge, New Jersey, USA
Address: 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA
To manage and expand Daiichi Sankyo's presence in the United States, a key market for pharmaceutical innovation and sales, and to conduct pivotal clinical trials.
Munich, Germany
Address: Zielstattstrasse 48, 81379 München, Germany
To drive the company's growth in the European pharmaceutical market, ensuring access to innovative medicines for patients across the region and navigating diverse regulatory landscapes.
Shanghai, China
Address: Unit 1201-1208, 12F, Tower C, The Place, No.100 Zunyi Road, Changning District, Shanghai, China
To address the increasing healthcare needs in China by providing innovative treatments and expanding the company's footprint in this strategically important Asian market.
Buying Intent Signals for Daiichi Sankyo
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Daiichi Sankyo
As of April 2025, Daiichi Sankyo' leadership includes:
Investors of Daiichi Sankyo
Daiichi Sankyo has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Daiichi Sankyo has seen some key leadership transitions and appointments aimed at strengthening its global oncology focus and research capabilities. Notably, changes in CEO and COO roles took effect April 1, 2023, reflecting strategic shifts within the company.
Departures
New Appointments:
Technology (Tech Stack) used by Daiichi Sankyo
Discover the tools Daiichi Sankyo uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Daiichi Sankyo Email Formats and Examples
Daiichi Sankyo commonly uses a combination of first name and last name, or first initial and last name, for their corporate email addresses. The domain is typically @daiichisankyo.com for global communications or country-specific domains like @daiichisankyo.us for regional offices.
[first].[last]@daiichisankyo.com or [first_initial][last]@daiichisankyo.com
Format
john.doe@daiichisankyo.com
Example
85%
Success rate
News and media
Daiichi Sankyo Press Release • May 28, 2024
Daiichi Sankyo news title: Daiichi Sankyo Announces Positive Topline Results from Phase 3 Trial of Valemetostat in Relapsed/Refractory Peripheral T-Cell Lymphoma
Daiichi Sankyo announced positive topline results from the pivotal VALENTINE-PTCL01 phase 3 trial evaluating valemetostat, an EZH1/2 dual inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The trial met its primary endpoint, demonstrating a statistically significant improvement in objective response rate....more
Daiichi Sankyo Financial Results • April 26, 2024
Daiichi Sankyo news title: Daiichi Sankyo Reports Strong Full-Year FY2023 Financial Results Driven by Oncology Portfolio Growth
Daiichi Sankyo reported its consolidated financial results for the fiscal year ended March 31, 2024, highlighting significant revenue growth primarily driven by the strong performance of its oncology products, particularly ENHERTU® and datopotamab deruxtecan....more
Fierce Pharma • March 5, 2024
Daiichi Sankyo news title: FDA Approves ENHERTU® for HER2-Positive Solid Tumors, Expanding Its Reach
The U.S. Food and Drug Administration (FDA) granted accelerated approval to ENHERTU® (trastuzumab deruxtecan), co-developed by Daiichi Sankyo and AstraZeneca, for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This marks a significant milestone as a tumor-agnostic approval....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Daiichi Sankyo, are just a search away.